CommercialCoverageMedium impact
08.00.99e, Belimumab (Benlysta®) for Intravenous Use
Independence Blue Cross·Rheumatology, Internal Medicine, Allergy & Immunology +1 more·Pharmacy
Effective date
Jul 22, 2026
We identified it
Jul 23, 2026
Summary
Policy 08.00.99e for Belimumab (Benlysta®) intravenous use has been reissued as of July 22, 2026. This is a pharmacy policy update for a biologic immunosuppressant medication used primarily in systemic lupus erythematosus (SLE) treatment. The billing team must review the updated coverage criteria, prior authorization requirements, and any changes to reimbursement guidelines to ensure compliant claims processing.
Action Required
By July 22, 2026: Billing team must obtain and review the complete updated policy text at the source URL to identify specific HCPCS codes (likely J codes for biologic drug administration), prior authorization requirements, and any documentation changes. Update billing system rules, prior auth templates, and provider communication materials to reflect any changes from the previous version. Notify prescribing providers (primarily rheumatology and internal medicine) of updated coverage criteria and documentation requirements. Any claims submitted after the effective date without compliance to the updated policy terms will be subject to denial. Contact the payer directly if the full policy text is not accessible online.